Elizabeth M Mcnally

List of Publications by Year in Descending Order

294 papers	14,779 citations	67 h-index	112 g-index
342 ext. papers	17,008 ext. citations	9.7 avg, IF	6.62 L-index

#	Paper	IF	Citations
294	Intermittent glucocorticoid treatment enhances skeletal muscle performance through sexually dimorphic mechanisms.. *Journal of Clinical Investigation*, **2022**,	15.9	2
293	Assessment of Virological Contributions to COVID-19 Outcomes in a Longitudinal Cohort of Hospitalized Adults.. *Open Forum Infectious Diseases*, **2022**, 9, ofac027	1	0
292	Case report: DSP truncation variant p. R1951X leads to arrhythmogenic left ventricular cardiomyopathy.. *European Heart Journal - Case Reports*, **2022**, 6, ytac105	0.9	
291	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study.. *Open Forum Infectious Diseases*, **2022**, 9, ofac055	1	2
290	PractitionersRConfidence and Desires for Education in Cardiovascular and Sudden Cardiac Death Genetics.. *Journal of the American Heart Association*, **2022**, e023763	6	
289	Muscle mitochondrial remodeling by intermittent glucocorticoid drugs requires an intact circadian clock and muscle PGC1□ *Science Advances*, **2022**, 8, eabm1189	14.3	0
288	Genotype and Cardiac Outcomes in Pediatric Dilated Cardiomyopathy.. *Journal of the American Heart Association*, **2021**, e022854	6	3
287	South Asian-Specific Deletion Carriers Display Hypercontraction and Impaired Diastolic Function Under Exercise Stress.. *Frontiers in Cardiovascular Medicine*, **2021**, 8, 766339	5.4	
286	Genetic correction strategies for Duchenne Muscular Dystrophy and their impact on the heart.. *Progress in Pediatric Cardiology*, **2021**, 63, 101460-101460	0.4	0
285	Resealing and rebuilding injured muscle. *Science*, **2021**, 374, 262-263	33.3	1
284	Geographic disparities in COVID-19 case rates are not reflected in seropositivity rates using a neighborhood survey in Chicago. *Annals of Epidemiology*, **2021**,	6.4	4
283	Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association. *Circulation*, **2021**, 144, e461-e471	16.7	0
282	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure **2021**,		6
281	Aortic Dissection With Pregnancy-Anticipating Prepartum and Postpartum Risk. *JAMA Cardiology*, **2021**, 6, 66-67	16.2	
280	Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2021**, 10, e019944	6	2
279	Genetic Variation in Enhancers Modifies Cardiomyopathy Gene Expression and Progression. *Circulation*, **2021**, 143, 1302-1316	16.7	4
278	Genetic Contribution to Common Heart Failure-Not So Rare?. *JAMA Cardiology*, **2021**, 6, 387	16.2	1

277	Practice Patterns After Return of Rare Variants Associated With Cardiomyopathy in the Electronic Medical Records and Genomics Network. *Circulation: Heart Failure*, **2021**, 14, e008155	7.6	
276	Patterns and persistence of SARS-CoV-2 IgG antibodies in Chicago to monitor COVID-19 exposure. *JCI Insight*, **2021**, 6,	9.9	10
275	Mitochondrial cardiomyopathy and ventricular arrhythmias associated with biallelic variants in C1QBP. *American Journal of Medical Genetics, Part A*, **2021**, 185, 2496-2501	2.5	2
274	COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men. *Journal of Infectious Diseases*, **2021**, 224, 793-797	7	11
273	Cohabitation With a Known Coronavirus Disease 2019 Case Is Associated With Greater Antibody Concentration and Symptom Severity in a Community-Based Sample of Seropositive Adults. *Open Forum Infectious Diseases*, **2021**, 8, ofab244	1	1
272	Identification of Cardiac Fibrosis in Young Adults With a Homozygous Frameshift Variant in SERPINE1. *JAMA Cardiology*, **2021**, 6, 841-846	16.2	2
271	Neptune: an environment for the delivery of genomic medicine. *Genetics in Medicine*, **2021**, 23, 1838-1848	8.1	1
270	Genetic Studies of Atrial Fibrillation in Diverse Cohorts and Identification of Diverse Phenotypes Associated With Single Genes. *JAMA Cardiology*, **2021**, 6, 820	16.2	
269	Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy. *Journal of Neuromuscular Diseases*, **2021**, 8, 39-52	5	13
268	Risk-Based Approach for the Prediction and Prevention of Heart Failure. *Circulation: Heart Failure*, **2021**, 14, e007761	7.6	3
267	Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel. *Open Heart*, **2021**, 8,	3	2
266	Transthyretin Genetic Testing. *JAMA Cardiology*, **2021**, 6, 849-850	16.2	
265	A surrogate virus neutralization test to quantify antibody-mediated inhibition of SARS-CoV-2 in finger stick dried blood spot samples. *Scientific Reports*, **2021**, 11, 15321	4.9	7
264	Knowing More Than the Knowns in Familial Hypercholesterolemia. *JAMA Cardiology*, **2021**, 6, 909	16.2	
263	Loss of dysferlin or myoferlin results in differential defects in excitation-contraction coupling in mouse skeletal muscle. *Scientific Reports*, **2021**, 11, 15865	4.9	1
262	Genomic Autopsy of Sudden Deaths in Young Individuals. *JAMA Cardiology*, **2021**, 6, 1247-1256	16.2	2
261	Durability of antibody response to vaccination and surrogate neutralization of emerging variants based on SARS-CoV-2 exposure history. *Scientific Reports*, **2021**, 11, 17325	4.9	9
260	Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals. *EClinicalMedicine*, **2021**, 38, 101018	11.3	21

259	Anti-latent TGF binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy. *Science Translational Medicine*, **2021**, 13, eabf0376	17.5	3
258	Expanding Discovery in Cardiovascular Genome-Wide Association Studies. *JAMA Cardiology*, **2021**, 6, 1012	16.2	1
257	Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study.. *Circulation*, **2021**,	16.7	2
256	Cardiac Macrophages - Keeping the Engine Running Clean. *New England Journal of Medicine*, **2020**, 383, 2474-2476	59.2	2
255	Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy. *Circulation*, **2020**, 141, 1872-1884	16.7	80
254	A role for alternative splicing in circadian control of exocytosis and glucose homeostasis. *Genes and Development*, **2020**, 34, 1089-1105	12.6	8
253	Clinical Care Recommendations for Cardiologists Treating Adults With Myotonic Dystrophy. *Journal of the American Heart Association*, **2020**, 9, e014006	6	13
252	Conference report on contractures in musculoskeletal and neurological conditions. *Muscle and Nerve*, **2020**, 61, 740-744	3.4	5
251	Pathogenic and Uncertain Genetic Variants Have Clinical Cardiac Correlates in Diverse Biobank Participants. *Journal of the American Heart Association*, **2020**, 9, e013808	6	10
250	Altered Enhancer and Promoter Usage Leads to Differential Gene Expression in the Normal and Failed Human Heart. *Circulation: Heart Failure*, **2020**, 13, e006926	7.6	2
249	A Small-Molecule Approach to Restore a Slow-Oxidative Phenotype and Defective CaMKII Signaling in Limb Girdle Muscular Dystrophy. *Cell Reports Medicine*, **2020**, 1, 100122	18	2
248	Prevalence of Abnormal Heart Weight After Sudden Death in People Younger than 40 Years of Age. *Journal of the American Heart Association*, **2020**, 9, e015699	6	3
247	High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. *PLoS ONE*, **2020**, 15, e0237833	3.7	48
246	Reporting Genetic Markers and the Social Determinants of Health in Clinical Cardiovascular Research-It Is Time to Recalibrate the Use of Race. *JAMA Cardiology*, **2020**,	16.2	3
245	Association of the V122I Transthyretin Amyloidosis Genetic Variant With Cardiac Structure and Function in Middle-aged Black Adults: Coronary Artery Risk Development in Young Adults (CARDIA) Study. *JAMA Cardiology*, **2020**,	16.2	1
244	Clinical utility of multigene analysis in over 25,000 patients with neuromuscular disorders. *Neurology: Genetics*, **2020**, 6, e412	3.8	15
243	238th ENMC International Workshop: Updating management recommendations of cardiac dystrophinopathyHoofddorp, The Netherlands, 30 November - 2 December 2018. *Neuromuscular Disorders*, **2019**, 29, 634-643	2.9	3
242	Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. *American Journal of Human Genetics*, **2019**, 105, 588-605	11	63

241	A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping. *DMM Disease Models and Mechanisms*, **2019**, 13,	4.1	9
240	Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. *Circulation Genomic and Precision Medicine*, **2019**, 12, e000054	5.2	28
239	Deletion of Sulfonylurea Receptor 2 in the Adult Myocardium Enhances Cardiac Glucose Uptake and Is Cardioprotective. *JACC Basic To Translational Science*, **2019**, 4, 251-268	8.7	4
238	Moderate exercise improves function and increases adiponectin in the mdx mouse model of muscular dystrophy. *Scientific Reports*, **2019**, 9, 5770	4.9	16
237	Spp1 (osteopontin) promotes TGF processing in fibroblasts of dystrophin-deficient muscles through matrix metalloproteinases. *Human Molecular Genetics*, **2019**, 28, 3431-3442	5.6	12
236	Risk Prediction Model in Children With Hypertrophic Cardiomyopathy: A Work in Progress. *JAMA Cardiology*, **2019**, 4, 927	16.2	4
235	Distinct pathological signatures in human cellular models of myotonic dystrophy subtypes. *JCI Insight*, **2019**, 4,	9.9	13
234	Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. *JCI Insight*, **2019**, 4,	9.9	14
233	Recombinant annexin A6 promotes membrane repair and protects against muscle injury. *Journal of Clinical Investigation*, **2019**, 129, 4657-4670	15.9	27
232	Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides. *Journal of Clinical Investigation*, **2019**, 129, 4570-4571	15.9	1
231	Dusp6 is a genetic modifier of growth through enhanced ERK activity. *Human Molecular Genetics*, **2019**, 28, 279-289	5.6	3
230	Reducing Racial/Ethnic Disparities in Cardiovascular Genetic Testing. *JAMA Cardiology*, **2018**, 3, 277-279	16.2	3
229	Non-Glycanated Biglycan and LTBP4: Leveraging the extracellular matrix for Duchenne Muscular Dystrophy therapeutics. *Matrix Biology*, **2018**, 68-69, 616-627	11.4	14
228	Association of Cardiomyopathy With MYBPC3 D389V and MYBPC3 25bpIntronic Deletion in South Asian Descendants. *JAMA Cardiology*, **2018**, 3, 481-488	16.2	21
227	Gene Editing and Gene-Based Therapeutics for Cardiomyopathies. *Heart Failure Clinics*, **2018**, 14, 179-188	3.3	6
226	A promoter interaction map for cardiovascular disease genetics. *ELife*, **2018**, 7,	8.9	78
225	Is Heart Failure Inherited?: Beyond the Cardiomyopathies, Genetics Do Matter. *JAMA Cardiology*, **2018**, 3, 710-711	16.2	1
224	Transgenic overexpression of the SUR2A-55 splice variant in mouse heart reduces infract size and promotes protective mitochondrial function. *Heliyon*, **2018**, 4, e00677	3.6	3

223	Prelamin A causes aberrant myonuclear arrangement and results in muscle fiber weakness. *JCI Insight*, **2018**, 3,	9.9	9
222	Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. *JCI Insight*, **2018**, 3,	9.9	11
221	Cardiac Management of the Patient With Duchenne Muscular Dystrophy. *Pediatrics*, **2018**, 142, S72-S81	7.4	37
220	New DEStiny Revealed: Young Woman Postablation for Wolf-Parkinson-White Syndrome With Recurrent Syncope and Progressive Myopathy. *Circulation*, **2018**, 138, 1267-1271	16.7	1
219	Myocarditis in Duchenne Muscular Dystrophy After Changing Steroids. *JAMA Cardiology*, **2018**, 3, 1006-1010	16.2	6
218	Genetic CounselorsRApproach To Postmortem Genetic Testing After Sudden Death: An Exploratory Study. *Academic Forensic Pathology*, **2018**, 8, 738-751	0.3	3
217	Novel nesprin-1 mutations associated with dilated cardiomyopathy cause nuclear envelope disruption and defects in myogenesis. *Human Molecular Genetics*, **2017**, 26, 2258-2276	5.6	59
216	Muscle cell communication in development and repair. *Current Opinion in Pharmacology*, **2017**, 34, 7-14	5.1	36
215	Outside in: The matrix as a modifier of muscular dystrophy. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2017**, 1864, 572-579	4.9	18
214	Cardiomyopathy in Muscular Dystrophy: When to Treat?. *JAMA Cardiology*, **2017**, 2, 199	16.2	6
213	Intermittent Glucocorticoid Dosing Improves Muscle Repair and Function in Mice with Limb-Girdle Muscular Dystrophy. *American Journal of Pathology*, **2017**, 187, 2520-2535	5.8	26
212	Dilated Cardiomyopathy: Genetic Determinants and Mechanisms. *Circulation Research*, **2017**, 121, 731-748	15.7	306
211	Mutation-Based Therapy for Duchenne Muscular Dystrophy: Antisense Treatment Arrives in the Clinic. *Circulation*, **2017**, 136, 979-981	16.7	7
210	Incorporating Genetic Testing Into Cardiovascular Practice. *JAMA Cardiology*, **2017**, 2, 1151-1152	16.2	1
209	Experimental Modeling Supports a Role for MyBP-HL as a Novel Myofilament Component in Arrhythmia and Dilated Cardiomyopathy. *Circulation*, **2017**, 136, 1477-1491	16.7	20
208	MicroRNAs promote skeletal muscle differentiation of mesodermal iPSC-derived progenitors. *Nature Communications*, **2017**, 8, 1249	17.4	14
207	Intermittent glucocorticoid steroid dosing enhances muscle repair without eliciting muscle atrophy. *Journal of Clinical Investigation*, **2017**, 127, 2418-2432	15.9	59
206	Genetic modifiers of muscular dystrophy act on sarcolemmal resealing and recovery from injury. *PLoS Genetics*, **2017**, 13, e1007070	6	13

205	Reproductive Aging and Cardiovascular Disease Risk. *JAMA Cardiology*, **2016**, 1, 778	16.2	3
204	Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease. *Skeletal Muscle*, **2016**, 6, 32	5.1	29
203	Pitx2 modulates a Tbx5-dependent gene regulatory network to maintain atrial rhythm. *Science Translational Medicine*, **2016**, 8, 354ra115	17.5	79
202	Plasma Membrane Repair in Health and Disease. *Current Topics in Membranes*, **2016**, 77, 67-96	2.2	45
201	An actin-dependent annexin complex mediates plasma membrane repair in muscle. *Journal of Cell Biology*, **2016**, 213, 705-18	7.3	100
200	Standard Operating Procedures (SOPs) for Evaluating the Heart in Preclinical Studies of Duchenne Muscular Dystrophy. *Journal of Cardiovascular Translational Research*, **2016**, 9, 85-6	3.3	10
199	Genotype-Specific Interaction of Latent TGF Binding Protein 4 with TGF *PLoS ONE*, **2016**, 11, e0150358	3.7	12
198	An actin-dependent annexin complex mediates plasma membrane repair in muscle. *Journal of Experimental Medicine*, **2016**, 213, 2137OIA58	16.6	1
197	BMP and WNT: the road to cardiomyocytes is paved with precise modulation. *Stem Cell Investigation*, **2016**, 3, 21	5.1	1
196	Welcome to the splice age: antisense oligonucleotide-mediated exon skipping gains wider applicability. *Journal of Clinical Investigation*, **2016**, 126, 1236-8	15.9	4
195	Thrombospondin expression in myofibers stabilizes muscle membranes. *ELife*, **2016**, 5,	8.9	27
194	Overexpression of Latent TGF Binding Protein 4 in Muscle Ameliorates Muscular Dystrophy through Myostatin and TGF *PLoS Genetics*, **2016**, 12, e1006019	6	26
193	Genetics of Cardiac Developmental Disorders: Cardiomyocyte Proliferation and Growth and Relevance to Heart Failure. *Annual Review of Pathology: Mechanisms of Disease*, **2016**, 11, 395-419	34	21
192	Enhanced Muscular Dystrophy from Loss of Dysferlin Is Accompanied by Impaired Annexin A6 Translocation after Sarcolemmal Disruption. *American Journal of Pathology*, **2016**, 186, 1610-22	5.8	20
191	Cardiac function in muscular dystrophy associates with abdominal muscle pathology. *Journal of Neuromuscular Diseases*, **2015**, 2, 39-49	5	5
190	Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy. *Circulation*, **2015**, 131, 1590-8	16.7	173
189	Disruption of the lamin A and matrin-3 interaction by myopathic LMNA mutations. *Human Molecular Genetics*, **2015**, 24, 4284-95	5.6	22
188	New approaches to establish genetic causality. *Trends in Cardiovascular Medicine*, **2015**, 25, 646-52	6.9	8

187	Membrane fusion in muscle development and repair. *Seminars in Cell and Developmental Biology*, **2015**, 45, 48-56	7.5	26
186	Genetic Variation in Cardiomyopathy and Cardiovascular Disorders. *Circulation Journal*, **2015**, 79, 1409-15	1.9	20
185	DNA Electroporation, Isolation and Imaging of Myofibers. *Journal of Visualized Experiments*, **2015**, e53551	1.6	16
184	Muscle hypertrophy induced by myostatin inhibition accelerates degeneration in dysferlinopathy. *Human Molecular Genetics*, **2015**, 24, 5711-9	5.6	31
183	The Dystrophin Complex: Structure, Function, and Implications for Therapy. *Comprehensive Physiology*, **2015**, 5, 1223-39	7.7	156
182	GRAF1 deficiency blunts sarcolemmal injury repair and exacerbates cardiac and skeletal muscle pathology in dystrophin-deficient mice. *Skeletal Muscle*, **2015**, 5, 27	5.1	11
181	Modifier genes and their effect on Duchenne muscular dystrophy. *Current Opinion in Neurology*, **2015**, 28, 528-34	7.1	36
180	Elizabeth McNally: A Muscular Approach. *Circulation Research*, **2015**, 117, 317-20	15.7	
179	The genetic landscape of cardiomyopathy and its role in heart failure. *Cell Metabolism*, **2015**, 21, 174-182	24.6	68
178	204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands. *Neuromuscular Disorders*, **2015**, 25, 184-98	2.9	16
177	Reengineering a transmembrane protein to treat muscular dystrophy using exon skipping. *Journal of Clinical Investigation*, **2015**, 125, 4186-95	15.9	24
176	Eps 15 Homology Domain (EHD)-1 Remodels Transverse Tubules in Skeletal Muscle. *PLoS ONE*, **2015**, 10, e0136679	3.7	10
175	Supercomputing for the parallelization of whole genome analysis. *Bioinformatics*, **2014**, 30, 1508-13	7.2	41
174	Targeted analysis of whole genome sequence data to diagnose genetic cardiomyopathy. *Circulation: Cardiovascular Genetics*, **2014**, 7, 751-759		43
173	P38 MAPK underlies muscular dystrophy and myofiber death through a Bax-dependent mechanism. *Human Molecular Genetics*, **2014**, 23, 5452-63	5.6	32
172	GRAF1 promotes ferlin-dependent myoblast fusion. *Developmental Biology*, **2014**, 393, 298-311	3.1	20
171	Abcc9 is required for the transition to oxidative metabolism in the newborn heart. *FASEB Journal*, **2014**, 28, 2804-15	0.9	14
170	Myofiber-specific inhibition of TGF signaling protects skeletal muscle from injury and dystrophic disease in mice. *Human Molecular Genetics*, **2014**, 23, 6903-15	5.6	32

169	EHD1 mediates vesicle trafficking required for normal muscle growth and transverse tubule development. *Developmental Biology*, **2014**, 387, 179-90	3.1	36
168	Genetic Modifiers for Neuromuscular Diseases. *Journal of Neuromuscular Diseases*, **2014**, 1, 3-13	5	21
167	The CO-Regulation Database (CORD): a tool to identify coordinately expressed genes. *PLoS ONE*, **2014**, 9, e90408	3.7	8
166	Genetic profiling for risk reduction in human cardiovascular disease. *Genes*, **2014**, 5, 214-34	4.2	11
165	Meeting Report: New Directions in the Biology and Disease of Skeletal Muscle 2014. *Journal of Neuromuscular Diseases*, **2014**, 1, 197-206	5	1
164	Excess SMAD signaling contributes to heart and muscle dysfunction in muscular dystrophy. *Human Molecular Genetics*, **2014**, 23, 6722-31	5.6	26
163	Modifiers of heart and muscle function: where genetics meets physiology. *Experimental Physiology*, **2014**, 99, 621-6	2.4	18
162	Targeting latent TGF release in muscular dystrophy. *Science Translational Medicine*, **2014**, 6, 259ra144	17.5	28
161	Exon-skipping therapy: a roadblock, detour, or bump in the road?. *Science Translational Medicine*, **2014**, 6, 230fs14	17.5	29
160	Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 6004-9	11.5	90
159	Dysferlin and myoferlin regulate transverse tubule formation and glycerol sensitivity. *American Journal of Pathology*, **2014**, 184, 248-59	5.8	43
158	Dynamin 2 the rescue for centronuclear myopathy. *Journal of Clinical Investigation*, **2014**, 124, 976-8	15.9	8
157	LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. *Annals of Neurology*, **2013**, 73, 481-8	9.4	145
156	Can we do better than dobutamine?. *Circulation Research*, **2013**, 113, 355-7	15.7	2
155	Modifying muscular dystrophy through transforming growth factor- *FEBS Journal*, **2013**, 280, 4198-209	5.7	40
154	Genetic mutations and mechanisms in dilated cardiomyopathy. *Journal of Clinical Investigation*, **2013**, 123, 19-26	15.9	293
153	Cytoskeletal Nuclear Links in the Cardiomyocyte **2013**, 123-140		
152	Population-based variation in cardiomyopathy genes. *Circulation: Cardiovascular Genetics*, **2012**, 5, 391-9		106

151	A KCNE1 missense variant (V47I) causing exercise-induced long QT syndrome (Romano Ward). *International Journal of Cardiology*, **2012**, 156, e33-5	3.2	4
150	The superhealing MRL background improves muscular dystrophy. *Skeletal Muscle*, **2012**, 2, 26	5.1	25
149	S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. *Journal of the American College of Cardiology*, **2012**, 60, 775-85	15.1	35
148	Genetic pathways of vascular calcification. *Trends in Cardiovascular Medicine*, **2012**, 22, 93-8	6.9	59
147	Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor- pathway. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 10978-83	11.5	82
146	Novel Targets and Approaches to Treating Skeletal Muscle Disease **2012**, 1095-1103		3
145	Interplay between heart and skeletal muscle disease in heart failure: the 2011 George E. Brown Memorial Lecture. *Circulation Research*, **2012**, 110, 749-54	15.7	6
144	Genetics: broken giant linked to heart failure. *Nature*, **2012**, 483, 281-2	50.4	13
143	TBX5 drives Scn5a expression to regulate cardiac conduction system function. *Journal of Clinical Investigation*, **2012**, 122, 2509-18	15.9	101
142	Advocacy: yes we can. *Journal of Clinical Investigation*, **2012**, 122, 4274-9	15.9	3
141	The attachment disorders of muscle: failure to carb-load. *Journal of Clinical Investigation*, **2012**, 122, 3046-8	15.9	
140	Emery-Dreifuss muscular dystrophy. *Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn*, **2011**, 101, 155-66	3	43
139	The emerging genetic landscape underlying cardiac conduction system function. *Birth Defects Research Part A: Clinical and Molecular Teratology*, **2011**, 91, 578-85		12
138	Genetic deletion of NOS3 increases lethal cardiac dysfunction following mouse cardiac arrest. *Resuscitation*, **2011**, 82, 115-21	4	14
137	Gene expression, chromosome position and lamin A/C mutations. *Nucleus*, **2011**, 2, 162-7	3.9	38
136	Cardiac magnetic resonance of left ventricular trabeculation: the new normal. *Circulation: Cardiovascular Imaging*, **2011**, 4, 84-6	3.9	4
135	S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 337-44	9.4	84
134	SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. *Human Molecular Genetics*, **2011**, 20, 894-904	5.6	31

133	Ferlin proteins in myoblast fusion and muscle growth. *Current Topics in Developmental Biology*, **2011**, 96, 203-30	5.3	46
132	Genetics of vascular calcification. *Circulation Research*, **2011**, 109, 248-9	15.7	4
131	Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. *Human Molecular Genetics*, **2011**, 20, 779-89	5.6	53
130	Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. *FASEB Journal*, **2011**, 25, 3106-14	0.9	36
129	Mechanisms and management of the heart in myotonic dystrophy. *Heart*, **2011**, 97, 1094-100	5.1	43
128	Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. *Journal of Biological Chemistry*, **2011**, 286, 7379-88	5.4	40
127	Vasodilation induced by oxygen/glucose deprivation is attenuated in cerebral arteries of SUR2 null mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 301, H1360-8	5.2	13
126	Hydrogen sulfide dilates cerebral arterioles by activating smooth muscle cell plasma membrane KATP channels. *American Journal of Physiology - Heart and Circulatory Physiology*, **2011**, 300, H2088-95	5.2	55
125	Distinct genetic regions modify specific muscle groups in muscular dystrophy. *Physiological Genomics*, **2011**, 43, 24-31	3.6	25
124	Altered chromosomal positioning, compaction, and gene expression with a lamin A/C gene mutation. *PLoS ONE*, **2010**, 5, e14342	3.7	88
123	Mechanisms of muscle weakness in muscular dystrophy. *Journal of General Physiology*, **2010**, 136, 29-34	3.4	50
122	Myoferlin is required for insulin-like growth factor response and muscle growth. *FASEB Journal*, **2010**, 24, 1284-95	0.9	44
121	Cardiomyocyte sulfonylurea receptor 2-KATP channel mediates cardioprotection and ST segment elevation. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1100-8	5.2	16
120	Myoferlin regulation by NFAT in muscle injury, regeneration and repair. *Journal of Cell Science*, **2010** , 123, 2413-22	5.3	37
119	S100A12 mediates aortic wall remodeling and aortic aneurysm. *Circulation Research*, **2010**, 106, 145-54	15.7	65
118	The mitochondrial bioenergetic phenotype for protection from cardiac ischemia in SUR2 mutant mice. *American Journal of Physiology - Heart and Circulatory Physiology*, **2010**, 299, H1884-90	5.2	11
117	The genetics of dilated cardiomyopathy. *Current Opinion in Cardiology*, **2010**, 25, 198-204	2.1	105
116	Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. *Journal of the American College of Cardiology*, **2010**, 55, 320-9	15.1	92

115	Ventricular fibrillation following autologous intramyocardial cell therapy for inherited cardiomyopathy. *Cardiovascular Pathology*, **2010**, 19, e33-6	3.8	8
114	Nesprin-1 mutations in human and murine cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2010**, 48, 600-8	5.8	112
113	Cardiac assessment in duchenne and becker muscular dystrophies. *Current Heart Failure Reports*, **2010**, 7, 212-8	2.8	74
112	Nesprins, but not sun proteins, switch isoforms at the nuclear envelope during muscle development. *Developmental Dynamics*, **2010**, 239, 998-1009	2.9	63
111	Mutation of SYNE-1, encoding an essential component of the nuclear lamina, is responsible for autosomal recessive arthrogryposis. *Human Molecular Genetics*, **2009**, 18, 3462-9	5.6	121
110	Molecular identification and functional characterization of a mitochondrial sulfonylurea receptor 2 splice variant generated by intraexonic splicing. *Circulation Research*, **2009**, 105, 1083-93	15.7	51
109	Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. *Circulation: Cardiovascular Genetics*, **2009**, 2, 442-9		77
108	Impaired exercise tolerance and skeletal muscle myopathy in sulfonylurea receptor-2 mutant mice. *American Journal of Physiology - Regulatory Integrative and Comparative Physiology*, **2009**, 297, R1144-53	3.2	9
107	Disruption of nesprin-1 produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. *Human Molecular Genetics*, **2009**, 18, 607-20	5.6	147
106	Setting the pace: Tbx3 and Tbx18 in cardiac conduction system development. *Circulation Research*, **2009**, 104, 285-7	15.7	12
105	Sarcomere mutations in cardiogenesis and ventricular noncompaction. *Trends in Cardiovascular Medicine*, **2009**, 19, 17-21	6.9	28
104	Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. *American Journal of Pathology*, **2009**, 175, 1817-23	5.8	47
103	Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. *Annual Review of Physiology*, **2009**, 71, 37-57	23.1	233
102	NO more muscle fatigue. *Journal of Clinical Investigation*, **2009**, 119, 448-50	15.9	33
101	Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. *Journal of Clinical Investigation*, **2009**, 119, 3703-12	15.9	123
100	Healing health care. *Journal of Clinical Investigation*, **2009**, 119, 2848	15.9	
99	Cardiac sulfonylurea receptor short form-based channels confer a glibenclamide-insensitive KATP activity. *Journal of Molecular and Cellular Cardiology*, **2008**, 44, 188-200	5.8	37
98	Long-term survival of transplanted stem cells in immunocompetent mice with muscular dystrophy. *American Journal of Pathology*, **2008**, 173, 792-802	5.8	12

97	Sarcomere mutations in cardiomyopathy, noncompaction, and the developing heart. *Circulation*, **2008**, 117, 2847-9	16.7	12
96	The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. *Journal of Biological Chemistry*, **2008**, 283, 20252-60	5.4	80
95	Sulfonylurea receptor-dependent and -independent pathways mediate vasodilation induced by ATP-sensitive K+ channel openers. *Molecular Pharmacology*, **2008**, 74, 736-43	4.3	34
94	A pilot study of a family history risk assessment tool for cardiovascular disease. *Journal of Genetic Counseling*, **2008**, 17, 499-507	2.5	8
93	Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. *Muscle and Nerve*, **2008**, 37, 308-16	3.4	63
92	Processing and assembly of the dystrophin glycoprotein complex. *Traffic*, **2007**, 8, 177-83	5.7	55
91	Cardiomyopathy in neuromuscular disorders. *Progress in Pediatric Cardiology*, **2007**, 24, 35-46	0.4	10
90	Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. *Trends in Cardiovascular Medicine*, **2007**, 17, 55-9	6.9	67
89	Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. *Journal of Biological Chemistry*, **2007**, 282, 10068-10078	5.4	31
88	Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. *Journal of Biological Chemistry*, **2007**, 282, 30745-53	5.4	82
87	Muscle diseases: the muscular dystrophies. *Annual Review of Pathology: Mechanisms of Disease*, **2007**, 2, 87-109	34	110
86	Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes. *Human Molecular Genetics*, **2007**, 16, 355-63	5.6	19
85	Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. *Human Molecular Genetics*, **2007**, 16, 2933-43	5.6	56
84	Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress. *Journal of Molecular and Cellular Cardiology*, **2007**, 43, 445-54	5.8	36
83	A novel FKRP mutation in congenital muscular dystrophy disrupts the dystrophin glycoprotein complex. *Neuromuscular Disorders*, **2007**, 17, 285-9	2.9	20
82	Genetic modifiers of muscular dystrophy: implications for therapy. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2007**, 1772, 216-28	6.9	17
81	New approaches in the therapy of cardiomyopathy in muscular dystrophy. *Annual Review of Medicine*, **2007**, 58, 75-88	17.4	83
80	Spontaneous coronary vasospasm in KATP mutant mice arises from a smooth muscle-extrinsic process. *Circulation Research*, **2006**, 98, 682-9	15.7	67

79	Hypertrophic cardiomyopathy: exercise and eat right. *Circulation Research*, **2006**, 98, 443-5	15.7	4
78	Skeletal Muscle Structure and Function **2006**, 674-681		
77	Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. *American Journal of Pathology*, **2006**, 168, 1975-85	5.8	84
76	Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. *Journal of the American College of Cardiology*, **2006**, 48, 1396-8	15.1	71
75	Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. *Experimental Cell Research*, **2005**, 303, 388-99	4.2	86
74	Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. *American Journal of Pathology*, **2005**, 167, 1309-20	5.8	154
73	Genetic background influences muscular dystrophy. *Neuromuscular Disorders*, **2005**, 15, 601-9	2.9	61
72	The interaction of coronary tone and cardiac fibrosis. *Current Atherosclerosis Reports*, **2005**, 7, 219-26	6	6
71	Normal myoblast fusion requires myoferlin. *Development (Cambridge)*, **2005**, 132, 5565-75	6.6	154
70	Therapy insight: cardiovascular complications associated with muscular dystrophies. *Nature Clinical Practice Cardiovascular Medicine*, **2005**, 2, 301-8		19
69	Inherited Myocardial Diseases **2005**, 105-122		
68	The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. *Circulation Research*, **2004**, 94, 1023-31	15.7	369
67	Powerful genes--myostatin regulation of human muscle mass. *New England Journal of Medicine*, **2004**, 350, 2642-4	59.2	52
66	Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle. *Journal of Cell Science*, **2004**, 117, 3821-30	5.3	62
65	Regenerating more than muscle in muscular dystrophy. *Circulation*, **2004**, 110, 3290-2	16.7	3
64	The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. *Nature Immunology*, **2004**, 5, 1052-60	19.1	899
63	Functional nitric oxide synthase mislocalization in cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2004**, 36, 213-23	5.8	30
62	Secondary coronary artery vasospasm promotes cardiomyopathy progression. *American Journal of Pathology*, **2004**, 164, 1063-71	5.8	29

61	Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. *Journal of Clinical Investigation*, **2004**, 113, 668-675	15.9	60
60	Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. *Journal of Clinical Investigation*, **2004**, 114, 1577-1585	15.9	84
59	Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. *Journal of Clinical Investigation*, **2004**, 114, 1577-85	15.9	24
58	Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. *Journal of Clinical Investigation*, **2004**, 113, 668-75	15.9	26
57	Sarcoglycans in vascular smooth and striated muscle. *Trends in Cardiovascular Medicine*, **2003**, 13, 238-43	6.9	30
56	Lamin A/C truncation in dilated cardiomyopathy with conduction disease. *BMC Medical Genetics*, **2003**, 4, 4	2.1	37
55	Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying nonsense Y259X heterozygous or homozygous mutation in lamin A/C gene. *Experimental Cell Research*, **2003**, 291, 352-62	4.2	143
54	Cytoskeletal defects in cardiomyopathy. *Journal of Molecular and Cellular Cardiology*, **2003**, 35, 231-41	5.8	22
53	Repairing the tears: dysferlin in muscle membrane repair. *Trends in Molecular Medicine*, **2003**, 9, 327-30	11.5	59
52	Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. *Human Molecular Genetics*, **2002**, 11, 2147-54	5.6	72
51	Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. *FASEB Journal*, **2002**, 16, 1096-8	0.9	19
50	Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. *Journal of Biological Chemistry*, **2002**, 277, 22883-8	5.4	146
49	Nesprin-1alpha self-associates and binds directly to emerin and lamin A in vitro. *FEBS Letters*, **2002**, 525, 135-40	3.8	200
48	Myosin Heavy Chain Gene Mutations in Familial Hypertrophic Cardiomyopathy. *Circulation Research*, **2002**, 90, 246-247	15.7	2
47	Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 KATP channels. *Journal of Clinical Investigation*, **2002**, 110, 203-208	15.9	159
46	Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. *Journal of Clinical Investigation*, **2002**, 110, 203-8	15.9	98
45	Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. *Journal of Cell Science*, **2002**, 115, 61-70	5.3	123
44	The sarcoglycan complex in striated and vascular smooth muscle. *Cold Spring Harbor Symposia on Quantitative Biology*, **2002**, 67, 389-97	3.9	16

43	Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. *Journal of Cell Science*, **2002**, 115, 61-70	5.3	112
42	Beta-myosin heavy chain gene mutations in familial hypertrophic cardiomyopathy: the usual suspect?. *Circulation Research*, **2002**, 90, 246-7	15.7	2
41	Mutations in the caveolin-3 gene: When are they pathogenic?. *American Journal of Medical Genetics Part A*, **2001**, 99, 303-7		36
40	Dysferlin protein analysis in limb-girdle muscular dystrophies. *Journal of Molecular Neuroscience*, **2001**, 17, 71-80	3.3	50
39	Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly. *Journal of Biological Chemistry*, **2001**, 276, 21785-90	5.4	42
38	Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. *Human Gene Therapy*, **2001**, 12, 205-15	4.8	123
37	Extraocular muscle is spared despite the absence of an intact sarcoglycan complex in gamma- or delta-sarcoglycan-deficient mice. *Neuromuscular Disorders*, **2001**, 11, 197-207	2.9	27
36	Cardiomyopathy in animal models of muscular dystrophy. *Current Opinion in Cardiology*, **2001**, 16, 211-7	2.1	14
35	Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation. *American Journal of Medical Genetics Part A*, **2000**, 91, 305-12		72
34	Sarcoglycans in muscular dystrophy. *Microscopy Research and Technique*, **2000**, 48, 167-80	2.8	103
33	Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. *Molecular Therapy*, **2000**, 1, 119-29	11.7	83
32	Myoferlin, a candidate gene and potential modifier of muscular dystrophy. *Human Molecular Genetics*, **2000**, 9, 217-26	5.6	134
31	Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. *Journal of Cell Biology*, **2000**, 148, 115-26	7.3	227
30	Severe gamma-sarcoglycanopathy caused by a novel missense mutation and a large deletion. *Neuromuscular Disorders*, **2000**, 10, 100-7	2.9	10
29	Dominant negative myostatin produces hypertrophy without hyperplasia in muscle. *FEBS Letters*, **2000**, 474, 71-5	3.8	167
28	Muscle degeneration without mechanical injury in sarcoglycan deficiency. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 10723-8	11.5	104
27	Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. *FEBS Letters*, **1998**, 422, 27-32	3.8	102
26	Caveolin-3 in muscular dystrophy. *Human Molecular Genetics*, **1998**, 7, 871-7	5.6	165

25	Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. *Journal of Cell Biology*, **1998**, 142, 1279-87	7.3	245
24	Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. *American Journal of Human Genetics*, **1997**, 61, 909-17	11	143
23	Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. *Human Molecular Genetics*, **1996**, 5, 1841-7	5.6	102
22	Deficiency of adhalin in a patient with muscular dystrophy and cardiomyopathy. *New England Journal of Medicine*, **1996**, 334, 1610-1	59.2	14
21	Beyond dystrophin. *Current Opinion in Pediatrics*, **1996**, 8, 569-582	3.2	59
20	The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. *Human Molecular Genetics*, **1996**, 5, 1963-9	5.6	139
19	Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. *Nature Genetics*, **1995**, 11, 266-73	36.3	405
18	Novel actin crosslinker superfamily member identified by a two step degenerate PCR procedure. *FEBS Letters*, **1995**, 368, 500-4	3.8	38
17	Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. *Science*, **1995**, 270, 819-22	33.3	469
16	Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. *Annals of Neurology*, **1995**, 38, 367-72	9.4	56
15	Human adhalin is alternatively spliced and the gene is located on chromosome 17q21. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 9690-4	11.5	82
14	Identification of sequences necessary for the association of cardiac myosin subunits. *Journal of Cell Biology*, **1991**, 113, 585-90	7.3	19
13	Hormonal modulation of a gene injected into rat heart in vivo. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 4138-42	11.5	160
12	Expression of myosin and actin in Escherichia coli. *Methods in Enzymology*, **1991**, 196, 368-89	1.7	21
11	Ventricular myosin light chain 1 is developmentally regulated and does not change in hypertension. *Nucleic Acids Research*, **1989**, 17, 2753-67	20.1	21
10	Bacterial expression of eukaryotic contractile proteins. *Cytoskeleton*, **1989**, 14, 3-11		11
9	Full-length rat alpha and beta cardiac myosin heavy chain sequences. Comparisons suggest a molecular basis for functional differences. *Journal of Molecular Biology*, **1989**, 210, 665-71	6.5	157
8	Complete nucleotide sequence of full length cDNA for rat alpha cardiac myosin heavy chain. *Nucleic Acids Research*, **1989**, 17, 7527-8	20.1	50

7	Coexpression and assembly of myosin heavy chain and myosin light chain in Escherichia coli. *Proceedings of the National Academy of Sciences of the United States of America*, **1988**, 85, 7270-3	11.5	28
6	Human cardiac myosin heavy chain genes and their linkage in the genome. *Nucleic Acids Research*, **1987**, 15, 5443-59	20.1	149
5	Myosin subfragment-1 is sufficient to move actin filaments in vitro. *Nature*, **1987**, 328, 536-9	50.4	456
4	A polymorphic human myosin heavy chain locus is linked to an anonymous single copy locus (D17S1) at 17p13. *Cytogenetic and Genome Research*, **1986**, 43, 117-20	1.9	34
3	Isolation and characterization of human myosin heavy chain genes. *Proceedings of the National Academy of Sciences of the United States of America*, **1983**, 80, 3716-20	11.5	84
2	A promoter interaction map for cardiovascular disease genetics		2
1	Symptoms of COVID-19 infection and magnitude of antibody response in a large community-based study		1